scholarly journals Molecular features of non‐anaplastic peripheral T‐cell lymphoma in children and adolescents

2021 ◽  
Author(s):  
Rex K. H. Au‐Yeung ◽  
Julia Richter ◽  
Ingram Iaccarino ◽  
Dmitriy Abramov ◽  
Chris M. Bacon ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Molecular Features

scholarly journals Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents

Blood ◽  
1992 ◽  
Vol 80 (11) ◽  
pp. 2938-2942 ◽  
Author(s):  
BG Gordon ◽  
PI Warkentin ◽  
DD Weisenburger ◽  
JM Vose ◽  
WG Sanger ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Phase I ◽  
Children And Adolescents ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
The Other ◽  
Peripheral T Cell Lymphoma

Abstract We report nine children with relapsed (n = 8) or high-risk (n = 1) peripheral T-cell lymphoma (PTCL) who underwent autologous (n = 6) or allogeneic (n = 3) bone marrow transplantation (BMT). These children received transplants as part of a prospective phase I/II study of thioTEPA (TT) and total body irradiation (TBI) with escalating doses of VP-16. The median age of these patients at time of BMT was 6.5 years (range 2.5 years to 14 years). Three were transplanted with active disease after failing salvage chemotherapy. Of the other six, one was transplanted in first complete remission (CR) and five in second or subsequent CR. Of these nine patients, eight are free of disease a median of 25 months after BMT (range, 6 to 48 months), with an estimated 2-year relapse-free survival (RFS) of 89%. Six of these eight patients have been followed for 12 or more months after BMT, and in each their current remission exceeds their longest previous remission duration. The toxicity of the TT/TBI +/- VP-16 regimens was significant but manageable, predominantly consisting of severe mucositis. For a comparison, we reviewed retrospective data on the six additional children and adolescents with PTCL who underwent BMT during the 3-year period preceding this phase I/II study. The median age at BMT of these six patients was 19 years (range 15.5 years to 20 years). These patients were prepared for BMT with a variety of other regimens. One had no response to BMT and the other five relapsed at 1.5 to 5 months after BMT (median, 3 months) with an RFS of 0%. Our data suggest that thioTEPA plus TBI, with or without VP-16, is an effective preparative regimen for BMT for young patients with relapsed or high-stage PTCL and leads to prolonged RFS.

Management of Peripheral T-Cell Lymphoma in Children and Adolescents Including STAT 3 Mutation Hyper-IgE Syndrome

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nikila Ravichandran ◽  
Ramya Uppuluri ◽  
Venkateswaran Vellaichamy Swaminathan ◽  
Kesavan Melarcode Ramanan ◽  
Satishkumar Meena ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Hyper Ige Syndrome

Peripheral T-Cell Lymphoma in Children and Adolescents: Role of Bone Marrow Transplantation

1994 ◽  
Vol 14 (1-2) ◽  
pp. 1-10 ◽  
Author(s):  
Bruce G. Gordon ◽  
Dennis D. Weisenburger ◽  
Warren G. Sanger ◽  
James O. Armitage ◽  
Peter F. Coccia
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Children And Adolescents ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma

Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases

2016 ◽  
Vol 95 (8) ◽  
pp. 1295-1305 ◽  
Author(s):  
K. Mellgren ◽  
◽  
A. Attarbaschi ◽  
O. Abla ◽  
S. Alexander ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
International Review ◽  
Peripheral T Cell Lymphoma

scholarly journals Non-anaplastic peripheral T-cell lymphoma in children and adolescents - a retrospective analysis of the NHL-BFM study group

2014 ◽  
Vol 168 (6) ◽  
pp. 835-844 ◽  
Author(s):  
Udo Kontny ◽  
Ilske Oschlies ◽  
Willi Woessmann ◽  
Birgit Burkhardt ◽  
Jasmin Lisfeld ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Retrospective Analysis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Study Group ◽  
Peripheral T Cell Lymphoma

Peripheral T-cell Lymphoma in Children and Adolescents

2012 ◽  
Vol 34 (8) ◽  
pp. 611-616 ◽  
Author(s):  
Rabah Al Mahmoud ◽  
Sheila Weitzman ◽  
Tal Schechter ◽  
Bo Ngan ◽  
Mohammed Abdelhaleem ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma

scholarly journals Peripheral T cell lymphoma (PTCL) in children and adolescents – a single centre experience

2019 ◽  
Vol 4 (2) ◽  
pp. S29 ◽  
Author(s):  
R. Nikila ◽  
Patel Shivani ◽  
M.R. Kesavan ◽  
V.S. Venkateswaran ◽  
Jayakumar Indira ◽  
...  
Keyword(s):  
T Cell ◽  
Children And Adolescents ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Single Centre ◽  
Peripheral T Cell Lymphoma ◽  
Single Centre Experience

scholarly journals Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents

Blood ◽  
1992 ◽  
Vol 80 (11) ◽  
pp. 2938-2942
Author(s):  
BG Gordon ◽  
PI Warkentin ◽  
DD Weisenburger ◽  
JM Vose ◽  
WG Sanger ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Phase I ◽  
Children And Adolescents ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
The Other ◽  
Peripheral T Cell Lymphoma

We report nine children with relapsed (n = 8) or high-risk (n = 1) peripheral T-cell lymphoma (PTCL) who underwent autologous (n = 6) or allogeneic (n = 3) bone marrow transplantation (BMT). These children received transplants as part of a prospective phase I/II study of thioTEPA (TT) and total body irradiation (TBI) with escalating doses of VP-16. The median age of these patients at time of BMT was 6.5 years (range 2.5 years to 14 years). Three were transplanted with active disease after failing salvage chemotherapy. Of the other six, one was transplanted in first complete remission (CR) and five in second or subsequent CR. Of these nine patients, eight are free of disease a median of 25 months after BMT (range, 6 to 48 months), with an estimated 2-year relapse-free survival (RFS) of 89%. Six of these eight patients have been followed for 12 or more months after BMT, and in each their current remission exceeds their longest previous remission duration. The toxicity of the TT/TBI +/- VP-16 regimens was significant but manageable, predominantly consisting of severe mucositis. For a comparison, we reviewed retrospective data on the six additional children and adolescents with PTCL who underwent BMT during the 3-year period preceding this phase I/II study. The median age at BMT of these six patients was 19 years (range 15.5 years to 20 years). These patients were prepared for BMT with a variety of other regimens. One had no response to BMT and the other five relapsed at 1.5 to 5 months after BMT (median, 3 months) with an RFS of 0%. Our data suggest that thioTEPA plus TBI, with or without VP-16, is an effective preparative regimen for BMT for young patients with relapsed or high-stage PTCL and leads to prolonged RFS.

Sign in / Sign up

Export Citation Format

Share Document